<DOC>
	<DOCNO>NCT02085980</DOCNO>
	<brief_summary>The purpose study assess safety efficacy laser treatment vulvovaginal atrophy ( VVA ) , assess change severity vaginal dryness symptom , mean visual analogic scale ( 10 cm VAS ) .</brief_summary>
	<brief_title>Clinical Investigation Assess Safety Efficacy Laser Treatment Vulvovaginal Atrophy</brief_title>
	<detailed_description>The laser handpiece ( probe ) deposit vaginal canal laser energy deliver handpiece . Subjects receive total three ( 3 ) treatment every six ( 6 ) week ( +/-1 week ) . Subjects return one week ( +/- 3 day ) post first treatment , well three ( 3 ) month ( +/- 2 week ) twelve ( 12 ) month ( +/- 2 week ) post third treatment .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>Healthy nonsmoking post menopausal woman absence menstruation least 12 month Exhibiting VVA symptom Prolapse stag &lt; II , accord pelvic organ prolapse quantification ( ICSPOPQ ) system Have procedure anatomical area 6 month prior treatment Understand accept obligation logistically able present schedule followup visit • Acute recurrent urinary tract infection ( UTI ) , genital infection ( e.g . herpes candida ) . Prolapse stag ≥ II , accord pelvic organ prolapse quantification ( ICSPOPQ ) system Any serious disease , chronic condition , could interfere study compliance Previously undergone reconstructive pelvic surgery Have use vaginal cream , moisturizers , lubricant homeopathic preparation least 3 month A history thrombophlebitis A history acute infection A history heart failure Received anticipate receive antiplatelets , anticoagulant , thrombolytic , vitamin E anti inflammatories within 2 week pre treatment Any medical condition , , investigator 's opinion would interfere patient 's participation study Taking medication photosensitive A history keloid formation</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>